Pseudomonas aeruginosa

Pseudomonas aeruginosa Pseudomonas aeruginosa is a versatile gram negative bacterium that grows in soil, marshes, and coastal marine habitats, as well as on plant and animal tissues. People with cystic fibrosis, burn victims, individuals with cancer, and persons infected with HIV are particularly at risk of disease resulting from Pseudomonas aeruginosa. Unlike many environmental bacteria, Pseudomonas aeruginosa has a remarkable capacity to cause disease in susceptible hosts. It

I. Description of P. aeruginosa Pseudomonas aeruginosa is characterized by aerobic, gram negative, motile, non-spore forming bacilli (rods).1 A trait that differentiates P. aeruginosa from other gram-negative bacteria is the fact that it produces indophenol oxidase, which is an enzyme that renders them positive in an oxidase test.1 The type of flagella this organism is known to possess is called a polar flagella, meaning a single flagellum at one pole of the rod.1 This means the motility of the organism

Pseudomonas aeruginosa in the Blood Agar is expected for the color of the media to stay the same. The colony should be grayish green, and it should produce a beta-hemolysis reaction, which completely destroys all the red blood cells and clears the Blood Agar. In the Brilliant Green Agar, the color of the media should stay the same. The colony should be pink, and it should be gram negative. In the Eosin Methylene Blue Agar, the color of the media should stay the same. There should be no growth in

Directed Evolution of Pseudomonas aeruginosa Lipase A Petroleum has long been a precious resource throughout history. Petroleum was likely used to construct asphalt that made the great towers and walls of Babylon (Leung, 1989). China used it to extract precious salt from seawater (Lerner, Wu, & Lin, 1964). Today, the world faces the challenge of creating enough fuel to satisfy the demands of a petroleum-dependent world. With the pressures of supply and demand ever increasing, industries around the

Pseudomonas aeruginosa is an opportunistic human pathogen and one of the leading causes of nosocomial infections worldwide [1]and causes a variety of infections especially in immunocompromised patients such as burned patients. Infections caused by P. aeruginosa are associated with significant morbidity and mortality [2, 3]. The organism exhibits a high level of intrinsic resistance and only a limited number of antimicrobial agents are active against it [4]. In addition, P. aeruginosa has acquired

Pseudomonas aeruginosa, a gram-negative, catalase, citrate, and oxidase positive, recognized by producing a blue green fluorescent pigment that commonly isolated from soil and water, water containing these bacteria can also contaminate food, and pharmaceutical products (Walker et al., 2004). It was reported that water with suboptimal levels of chlorine can collaborate the survival of Pseudomonas aeruginosa (Shrivastava and Upreti, 2004). Pseudomonas aeruginosa is a pathogen capable of infecting

Pseudomonas aeruginosa (P. aeruginosa) is an important Gram-negative opportunistic pathogen that has the capability to create variable clinical infections including, but not limited to, wound infections, urinary tract infections (UTIs) and blood stream infections (BSI), particularly in hospitalized and immunocompromised patients (1, 2). P. aeruginosa was the second most common cause of hospital-acquired pneumonia, third and fifth common cause of hospital-acquired UTIs in USA and Europe, respectively

Healthcare-associated pneumonia (HAP) is a common complication of being hospitalized, especially in the elderly. On average, HAP increases the length of stay (LOS) to seven to nine days, adds $40,000 to $65,000 in cost of care, and is a big contributor to morbidity and mortality risks (Quinn, et al., 2014). The World Health Organization reports that 1.4 million people die annually related to pneumonia infections (Driver, 2012). A comparison of community-acquired pneumonia (CAP) and HAP indicates

In this article “Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection: Clinical Implications of an Extended-Infusion Dosing Strategy,” (2007), Thomas P. Lodise, Jr., Ben Lomaestro, and George L. Drusano evaluate the clinical outcomes among critically ill patients with pseudomonas aeruginosa (P. aeruginosa) infection, to examine if extended infusion of piperacillin-tazobactam produced results superior to the standard intermittent administration of these drug by using a Monte Carlo simulation

The aim of this project is to develop two bioanalytical sensing platforms as a means to study phenomena in organized 3D cellular microenvironments that appropriately model key aspects of biological habitats. Three important questions, listed below, will be addressed during this project, which we discuss in detail in Sections 3.1-3.3. (1) Can we determine concentrations of cellular biogenic species (NO, H2O2) in organized microcommunities using T-CUAs? (2) Can we monitor proximity-dependent cellular